Keyphrases
Glucagon-like
100%
Type 2 Diabetes Mellitus (T2DM)
58%
Type 2 Diabetic Patients
54%
Roux-en-Y Gastric Bypass
52%
Liraglutide
37%
Glucose-dependent Insulinotropic Polypeptide
36%
Glucagon
33%
Weight Loss
33%
Type 1 Diabetes Mellitus (T1DM)
31%
Type I Diabetes
30%
Insulin
30%
Obesity
26%
Insulin Sensitivity
25%
A1 Receptor
23%
Receptor Agonist
22%
Insulin Secretion
22%
Skeletal muscle
21%
Insulin Resistance
21%
Glycemic Control
21%
Hemoglobin A1c (HbA1c)
18%
Placebo
18%
Insulinotropic Effects
17%
Insulin Therapy
16%
Metformin
15%
Incretin Hormones
15%
Non-diabetic
15%
Medicine and Dentistry
Glucagon Like Peptide 1
70%
Roux-en-Y Gastric Bypass
50%
Maturity Onset Diabetes of the Young
49%
Diabetes Mellitus
31%
Gastric Inhibitory Polypeptide
30%
Insulin Release
29%
Patient with Type 2 Diabetes
29%
Insulin Sensitivity
26%
Secretion (Process)
25%
Incretin
22%
Beta Cell
22%
Placebo
21%
Cell Function
20%
Diabetes
20%
Liraglutide
20%
Glycemic Control
18%
Gastric Bypass Surgery
18%
Glucose Tolerance
18%
Insulin Resistance
18%
Glucose Metabolism
16%
Glucagon-Like Peptide-1 Agonist
16%
Glucagon
15%
Biochemistry, Genetics and Molecular Biology
Glucagon-Like Peptide-1
55%
Gastric Inhibitory Polypeptide
34%
Glucagon
29%
Insulin Release
27%
Glucose Blood Level
23%
Insulin Resistance
23%
Incretin
20%
Skeletal Muscle
18%
Insulin Sensitivity
17%
Human immunodeficiency virus
15%
